GSK and Novo Nordisk Lead on Access Index
Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries.
Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries.
For the fourth time, GSK leads the index with Novo Nordisk taking second. J&J. Novartis, Gilead and Merck KGaA rank three to six with nearly even scores.
Download the report here.
Novo Nordisk leapt from sixth to second with improvements in five of the seven areas the index analyzes.
Also making impressive gains in index rankings were Novartis, Merck KGaA and Eisai. Some companies that took tumbles in the rankings were Pfizer, Eli Lilly and Takeda.
Astellas, Daiichi Sankyo and Takeda are at the bottom of the index ranking 18th, 19th and 20th.
The index is built on business activity in seven areas with four strategic pillars considered in each.
The foundation has refined what it measures and how it assesses the evidence resulting in “a clearer picture of industry strengths, weaknesses, progress and struggles – and a crystallised understanding of what it takes to be a leader in access to medicine,” according to Wim Leereveld, Index CEO and Founder.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
